Trial Profile
A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Proof of concept; Therapeutic Use
- Acronyms BLOSSOM
- Sponsors Astellas Pharma Europe Ltd
- 28 May 2012 integrated information from CT.gov; patient number = 262 according to ct.gov (actual or planned?) left no. from results doc unchanged. tool won't let me rearrange groups...
- 05 Nov 2010 New trial record.